Stocks Celgene Corp


  • Nov 5- Celgene Corp posted its smallest revenue growth in five quarters as sales of its blockbuster cancer treatment Revlimid slowed. Celgene's shares fell 4.5 percent to $121.55 in early trading on Thursday after the company also reported a profit that barely topped analysts' estimates. The company also cut its full-year profit view to $2.02- $2.24 per share...

  • *HomeAway surges after Expedia's buyout offer. *Qualcomm, Whole Foods down after weak results. "It's going to be a quiet day... as people are going to be squaring positions and getting set up," said Matthew Tuttle, chief executive of Tuttle Tactical Management in Stamford, Connecticut.

  • Futures higher; jobs report in focus Thursday, 5 Nov 2015 | 8:43 AM ET
    A trader works on the floor of the New York Stock Exchange.

    U.S. stock index futures indicated a higher open on Thursday as traders awaited Friday's key employment report.

  • UPDATE 1-Celgene profit edges past estimates Thursday, 5 Nov 2015 | 8:04 AM ET

    Nov 5- Drugmaker Celgene Corp reported a quarterly profit that beat estimates by its smallest margin in nearly two years. Celgene's shares fell 4 percent after the company also posted its slowest revenue growth in five quarters. Celgene posted net loss of $34.1 million, or 4 cents per share, in the third quarter, compared with a net profit of $508.5 million, or 61...

  • Nov 5- Drugmaker Celgene Corp posted an 18 percent jump in quarterly revenue as demand for its cancer and psoriasis drugs increased. The company's revenue rose to $2.33 billion in the quarter ended Sept. 30 from $1.98 billion a year earlier. Celgene posted a net loss of $34.1 million, or 4 cents per share, in the quarter compared with a net profit of $508.5 million, or...

  • Trading Facebook and FireEye ahead of earnings Wednesday, 4 Nov 2015 | 2:22 PM ET

    The "Halftime Report" traders give their trades ahead of earnings.

  • Markets to tune out Fed speakers in favor of data Friday, 30 Oct 2015 | 6:28 PM ET
    A trader works on the floor of the New York Stock Exchange on Aug. 24, 2015, in New York City.

    Markets will be laser-focused on Friday's October jobs report in the week ahead and may even look past more than a dozen scheduled Fed speeches.

  • Oct 16- The most influential source for U.S. oncology treatment guidelines on Friday unveiled ratings aimed at helping doctors and patients assess the costs versus benefits of current therapies for two types of blood cancer. Craig Hofmeister, a hematologist with the Ohio State University Comprehensive Cancer Center and a member of the NCCN myeloma...

  • In examples released on Friday, NCCN rated primary treatments for CML: Bristol-Myers Squibb's Sprycel, and Novartis AG's Gleevec and Tasigna. For newly diagnosed myeloma patients eligible for a stem cell transplant, NCCN lists six "preferred" regimens, four of which contain Takeda Pharmaceutical Co's Velcade and various chemotherapies, one that includes...

  • At least half a dozen drugs, including colon cancer treatments Cyramza, from Eli Lilly& Co, and Stivarga, sold by Bayer AG, aren't worth prices that can exceed $100,000 a year, top cancer specialists said in interviews with Reuters. If specialists do start considering a drug's cost in their prescribing habits, such decisions could dent the multibillion-dollar...

  • Oct 6- The S&P and the Nasdaq fell on Tuesday morning as worries about economic growth resurfaced at U.S. companies begin to report quarterly results, while a surge in DuPont helped the Dow move higher. DuPont rose 11.1 percent to $56.96 after CEO Ellen Kullman said she would step down. The International Monetary Fund cut its global growth forecasts for a second...

  • NEW YORK/ ATLANTA, Oct 5- The Pacific trade deal agreed on Monday, which grants biotechnology drug producers less protection than offered by the United States, could put more downward pressures on the costly drugs' pricing in the industry's most lucrative market. The United States and 11 trading partners, including Mexico, Japan, Canada and Australia, wrapped up...

  • US STOCKS-Futures rise as investors await host of data Thursday, 1 Oct 2015 | 7:24 AM ET

    Oct 1- U.S. stock index futures started the last quarter of the year on a positive note on Thursday as weak data from China raised hopes of more stimulus measures from Beijing and investors awaited a slew of U.S. data. *Data showed factory activity in China shrank again in September, leading some investors to believe that the government will be more aggressive in its...

  • Patent and Trademark Office on Friday denied a request by Celgene Corp to sanction Bass and his Coalition for Affordable Drugs by throwing out their challenges to its patents. Celgene in July accused Bass of abusing the patent review process by short-selling pharmaceutical shares that drop when a patent review is filed. A spokeswoman for Bass' $2 billion...

  • Lightning Round: It's a winner, don't back away Friday, 25 Sep 2015 | 7:13 PM ET
    Mad Money Lightning Round

    Jim Cramer gives his opinion on caller favorite stocks, including this stock that was recently taken to the woodshed.

  • What a week for biotechs: Drop into bear territory Friday, 25 Sep 2015 | 3:33 PM ET

    Biotechnology stocks deepened their rout Friday, as fears of drugs prices continued to mount.

  • NEW YORK, Sept 25- The S&P 500 and Nasdaq turned lower in afternoon trading, dragged down by a drop in biotech shares. The Nasdaq Biotech Index was down 6.2 percent, led lower by a 5.6 percent drop in Celgene. Democratic presidential candidate Hillary Clinton said she would announce a plan to stop "price gouging" for specialty drugs, sparking a fall in the shares.

  • Biotech bounce after Hillary smackdown? Wednesday, 23 Sep 2015 | 11:59 AM ET

    Some biotech stocks may be poised to rise in the days ahead as technical traders step in to buy oversold names in the space.

  • Sept 23- Drug developer OncoGenex Pharmaceuticals Inc said its experimental combination therapy for pancreatic cancer was not effective in a mid-stage study. The intravenous drug, apatorsen, when added to Celgene Corp's combination treatment of Abraxane and chemotherapy drug gemcitabine, did not show any survival benefit when compared with the Abraxane...

  • These outperforming stocks are looking risky Wednesday, 16 Sep 2015 | 6:00 AM ET
    Traders work on the floor of the New York Stock Exchange (NYSE) in New York City.

    Big tech names such as Facebook and Google have excelled this year, but one trader says the large cap tech ETF is a risky buy.